Skip to content
Screener

Allogene Therapeutics ALLO Business Segments — Supporting external spend

Similar metrics at other companies

Martin Marietta Materials logo
MLMReportable Segments — External Freight Expense
$103M+37.3%
LanzaTech Global, Inc. logo
LNZAReportable Segment — External Service Providers Expenses
$3.55M-63.0%
Precigen logo
PGENReportable Segment — Revenues from external customers
$2.42M+147%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — External research and development
$27.73M+24.0%
Incyte logo
INCYReportable Segment — Research and development - external
$248.34M+1.1%
Akamai Technologies logo
AKAMReportable Segment — Network build-out and supporting services
$74.42M+27.8%

Other financials

Income statement

See full
Revenue-
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$693.76M+205%
Enterprise value$734.21M+192%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Reported directly by Allogene Therapeutics in its filing.

Tagged under the XBRL concept allo:SupportingExternalSpendExpense.

The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034585
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
All other development costs1,99910,390
Payroll14,44419,601
Facilities & IT-related spend6,4187,319
Supporting external spend4,3725,846
Other operating expenses11,19015,813
Total operating expenses46,09265,191
Other income (expenses), net3,4855,458
Net loss(42,607)(59,733)

Item 1. Financial Statements - Unaudited

FAQ

What is Allogene Therapeutics's business segments — supporting external spend?
Allogene Therapeutics (ALLO) reported business segments — supporting external spend of $4.37M in Q1 2026.
How has Allogene Therapeutics's business segments — supporting external spend changed year-over-year?
Allogene Therapeutics's business segments — supporting external spend decreased by 25.2% year-over-year, from $5.85M to $4.37M.
What is the long-term trend for Allogene Therapeutics's business segments — supporting external spend?
Over 2 years (2023 to 2025), Allogene Therapeutics's business segments — supporting external spend has grown at a -30.8% compound annual growth rate (CAGR), from $43.25M to $20.7M.
What does business segments — supporting external spend mean?
This metric encompasses payments to third-party vendors, contract research organizations, and consultants that provide essential support for clinical and operational activities. It reflects the company's reliance on external partnerships to execute its development pipeline. Fluctuations in this metric highlight the company's outsourcing strategy and variable cost management.

Ask your AI about Allogene Therapeutics's business segments — supporting external spend.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude